Carbamazepine for seizures and trigeminal neuralgia pain

Carbamazepine extended-release tablets are oral medications used primarily to control certain types of seizures and to treat the pain associated with trigeminal neuralgia. These tablets slowly release carbamazepine to maintain therapeutic levels over time.

Seizure control: Used as an anticonvulsant to treat partial seizures with complex symptoms (psychomotor, temporal lobe), generalized tonic-clonic seizures (grand mal), and mixed seizure patterns involving these seizure types. It is not effective for absence (petit mal) seizures.

Trigeminal neuralgia pain: Prescribed to relieve pain from true trigeminal neuralgia and has shown beneficial effects in glossopharyngeal neuralgia. This medication is not for general pain relief or minor aches.

Carbamazepine

Carbamazepine acts by suppressing abnormal electrical activity in the brain that causes seizures and neuralgic pain. It reduces polysynaptic responses and blocks post-tetanic potentiation, though its exact mechanism in humans is not fully understood. Its active metabolite, carbamazepine-10,11-epoxide, also has anticonvulsant activity.

Carbamazepine extended-release tablets are taken orally, available in 100 mg, 200 mg, and 400 mg strengths. The exact dosing schedule is individualized based on patient response and condition. Extended-release tablets provide steadier blood levels compared to conventional formulations, with peak plasma concentrations occurring 3 to 12 hours after dosing. The half-life decreases over several weeks due to autoinduction of metabolism, from 25-65 hours initially to 12-17 hours after chronic use. Therapeutic plasma levels in adults typically range from 4 to 12 mcg/mL.

• History of bone marrow depression.
• Hypersensitivity to carbamazepine or tricyclic compounds (e.g., amitriptyline, imipramine).
• Concurrent use with MAO inhibitors or nefazodone.
• Known sensitivity to carbamazepine or related compounds.

• Serious skin reactions: Severe and sometimes fatal dermatologic reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can occur, especially in patients with the HLA-B*1502 allele common in some Asian populations. Patients with this allele should generally avoid carbamazepine unless benefits outweigh risks. Discontinue drug immediately if rash develops.
• Blood disorders: Aplastic anemia and agranulocytosis have been reported. Baseline and ongoing blood counts are recommended. Discontinue if significant bone marrow suppression occurs.
• Drug hypersensitivity: Includes drug reaction with eosinophilia and systemic symptoms (DRESS), which can involve multiple organs and be life-threatening.
• Suicidal thoughts and behavior: Antiepileptic drugs including carbamazepine increase the risk of suicidal ideation. Patients should be monitored for mood changes or suicidal behavior throughout treatment.
• Other risks: May cause mild anticholinergic effects and increased intraocular pressure; caution in patients with glaucoma. May activate latent psychosis or cause confusion, especially in elderly.

• Common side effects: Transient leukopenia or mild decreases in blood counts.
• Serious side effects: Stevens-Johnson syndrome, toxic epidermal necrolysis, aplastic anemia, agranulocytosis, DRESS hypersensitivity, anaphylaxis, and angioedema with potential fatal airway obstruction.

• Coadministration with nefazodone is contraindicated due to lowered plasma concentrations of nefazodone and its active metabolite, reducing therapeutic effect.
• Carbamazepine induces cytochrome P450 enzymes affecting levels of concomitant drugs; concentrations of carbamazepine and other drugs may increase or decrease during therapy, requiring close monitoring.
• Should not be used concurrently with monoamine oxidase (MAO) inhibitors; MAO inhibitors must be discontinued at least 14 days prior.